Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase, the aim ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...

British scientists have become the first in the world to use a pioneering gene therapy to preserve sight in toddlers with the ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...

Cell and gene therapy tout promising results, but manufacturing challenges around personalized treatments require industry ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an osteoarthritis treatment in human trials may have potential for treating RA.

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, ...